Ambrisentan C₂₂H₂₂N₂O₄

Therapeutic indications

Ambrisentan is indicated for:

Pulmonary arterial hypertension (PAH) classified as WHO functional class II and III

Population group: both men and women, only adults (18 years old or older)

Ambrisentan is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ambrisentan is contraindicated in the following cases:

Severe hepatic impairment

Hepatic failure stage IV

Pregnancy

Pregnancy

Lactation

Lactation

Idiopathic pulmonary fibrosis

Other interstitial pulmonary diseases with fibrosis

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: VOLIBRIS Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈